Brewin Dolphin, one of the largest independent private client investment managers, is delighted to be sponsoring Geoff Thomas and his Leukaemia & Lymphoma Research cycle team in the prestigious London to Paris (L2P) cyclosportive. The event will take place over 3 days from the 23rd June and all money raised will help beat blood cancers.
10 Brewin Dolphin employees from across the country will join Geoff’s 45-strong team covering 520km for the L2P 2011, known as the “professional event for amateur riders”. Peter Land, a Divisional Director at Brewin Dolphin’s office in London is part of the cycling team.
Peter Land said, “I am delighted to be part of this exciting event, cycling to Paris is a challenge I never imagined possible. But Geoff is an inspiration and we are all so glad to be helping the work of this fantastic charity’.
Geoff, a former England footballer, was diagnosed with chronic myeloid leukaemia in 2003 and following intensive treatment has made a full recovery. Since then, he has devoted himself to fundraising to find a cure for blood cancers. He is a very keen cyclist having ridden the L2P and the Tour de France on a number of occasions.
Geoff is working in partnership with leading blood cancer charity Lymphoma & Leukaemia Research and has been pivotal in the setting up of a new national initiative to speed up development of new life-saving drugs at specialist blood cancer units across the country.
St Bartholomew’s Hospital, Kings College Hospital and Imperial College Healthcare NHS Trust have all been named as centre’s in this unique new clinical trials network, which will give blood cancer patients access to millions of pounds worth of life saving drugs.
These are just three out of 13 centres in the national network, set up by the charity Leukaemia & Lymphoma Research in response to poor survival rates for many types of leukaemia, lymphoma and myeloma.
St Barts, Kings and Imperial College hospital will be allocated research nurses to help recruit patients who are not responding to current treatment. They will also manage clinical trials data associated with clinical trials for promising new drugs.
By linking clinical trials centres to other hospitals in the new national network, individual patients with blood cancers, traditionally seen as rarer cancers, will have access to new drugs at a centres near them. The first trials are expected to be entered into the network by the end of the year.
To sponor the team please go to http://www.justgiving.com/brewindolphincycle